Intellia rises after enrolling patients in late-stage trial of genetic disorder drug
18/09/2025 13:13
** Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 5.3% to $13.07 premarket ** Company says it has completed enrolling patients in a late-stage study of its experimental therapy, lonvoguran ziclumeran (lonvo-z), for the treatment of hereditary angioedema ** Hereditary Angioedema is characterized by severe, recurring, and unpredictable swelling attacks in parts of the body including the skin, gastrointestinal tract, and airways ** Company expects late-stage study data in H1 2026 ** Intellia says it is on track to submit a biologics license application in H2 2026 to support the company's plans for a potential U.S. launch in H1 2027 ** As of last close, stock up 6.4% YTD (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)